Canadian Task Force on Preventive Health Care

Selected References

Preventive Health Care, 2005 Update: Screening for Type 2 Diabetes Mellitus to Prevent Vascular Complications

Prepared  by D.S. Feig, MD, MSc, FRCPC, V.A. Palda, MD, MSc, FRCPC, L. Lipscombe, with the Canadian Task Force on Preventive Health Care

  1. Harris R, Donahue K, Rathore SS, Frame P, Woolf SH, Lohr KN. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003;138(3):215-29.
  2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [ADA position paper]. Diabetes Care 2003;26(1):S5-20.
  3. Canadian Diabetes Association Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Screening and prevention. Can J Diabetes 2003;27(Suppl 2):S10-3.
  4. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004;27(Suppl 1):S11-4.
  5. US Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. Ann Intern Med 2003;138(3): 212-4.
  6. Blunt BA, Barrett-Connor E, Wingard DL. Evaluation of fasting plasma glucose as a screening test for NIDDM in older adults. Ranco Bernardo Study. Diabetes Care 1991;14:989-93.
  7. Lee CH, Rook Chong S. Evaluation of fasting plasma glucose as a screening test for diabetes mellitus in Singaporean adults. Diabet Med 1997;14:119-22.
  8. Chang CJ, Wu JS, Lu FH Lee HL, Yang YC, Wen MJ. Fasting plasma glucose in screening for diabetes in the Taiwanese population. Diabetes Care 1998;21:1856-60.
  9. Wiener K. Fasting plasma glucose as a screening test for diabetes mellitus. Diabet Med 1997;14:711-2.
  10. Bennett PH, Rushforth NB, Miller M, Lecompte PM. Epidemiologic studies of diabetes in Pima Indians. Recent Prog Horm Res 1976;32:333-76.
  11. McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes [published erratum in BMJ 1994;309:841]. BMJ 1994;308:1323-8.
  12. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes; diagnostic criteria and performance revisited. Diabetes Care 1997;20:785-91.
  13. Engelgau M, Narayan KNV, Herman W. Screening for type 2 diabetes. Diabetes Care 2000;23:1563-80.
  14. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance test in a general Caucasian population; the Hoorn Study. Diabetologia 1996;39:298-305.
  15. UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
  16. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
  17. UKPDS 38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13.
  18. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.
  19. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl 2):B54-B64.
  20. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
  21. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.
  22. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
  23. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
  24. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
  25. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
  26. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analysis in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7.
  27. Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN. Screening and treating adults for lipid disorders. Am J Prev Med 2001;20 (Suppl 3):77-89.
  28. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
  29. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91.
  30. Goldberg RB, Mellies MJ, Sacks FM, Moy LA, Howard BV, Howard WJ, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels; subgroup analyses and the Cholesterol and Recurrent Events (CARE) trial. The CARE investigators. Circulation 1998;98:2513-9.
  31. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20(4):537-44.
  32. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343-50.
  33. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
  34. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290(4): 486-494.
  35. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. Lancet 2002;359:2072-7.
  36. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003;26(4):977-80.
  37. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Impact of diabetes screening on quality of life. Diabete Care 2002;25:1022-6.
  38. Eriksson KE, Lindgarde F. Impaired glucose tolerance in a middle-aged male urban population: a whole new approach for identifying high-risk cases. Diabetologia 1990;33:526-31.
  39. Yudkin JS, Alberti KGMM, McLarty DG, Swai ABM. Impaired glucose tolerance: Is it a risk factor for diabetes or a diagnostic ragbag? BMJ 1990;301:397-401.
  40. Balkau B, Eschwege E. Repeatability of the oral glucose tolerance test for the diagnosis of impaired glucose tolerance and diabetes mellitus. Diabetologia 1991;34:201-2.
  41. Ramaiya KL, Swai ABM, McLarty DG, Kitange HM, Alberti KGMM. Improvement in glucose tolerance after one year of follow-up in a Hindu community in Africa. Diabet Res Clin Pract 1990;10:245-55.
  42. Swai AB, McLarty DG, Kitange HM, Kilima PM, Masuki G, Mtinangi BI, et al. Study in Tanzania of impaired glucose tolerance: Methodological myth? Diabetes 1991;40(4):516-20.
  43. Bourn DM, Williams SM, Mann JI. Distinguishing between persistent and transient impaired glucose tolerance using a prediction model. Diabet Med 1992;9:744-8.
  44. Warram JH, Sigal RJ, Martin BC, Krolewski AS, Soeldner JS. Natural history of impaired glucose tolerance: follow-up at Joslin Clinic. Diabet Med 1996;13:S40-5.

Link to Published Recommendation Statement

Link to Full Technical Report (in pdf)

Link to Summary Table of Recommendations of this review

Top of Page

CTFPHC Home Page

Reprinted in modified format by the Canadian Task Force on Preventive Health Care
Original Copyright © 2000 Canadian Medical Association.
For any technical issues please contact: webmaster@ctfphc.org
Last modified: February 02, 2005